This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Verona Pharma plc
Drug Names(s): VRP700
Description: The mechanism of action of VRP700 is presumed to involve the suppression of cough initiating signals originating at cough sensory nerve endings located in the lungs via a novel mechanism.
Deal Structure: In November 2007, Verona Pharma announced that it has acquired significant know-how from a North American biotechnology company for a potential anti-tussive drug in return for a low, single digit royalty on all future milestone payments resulting from any licensing agreements.
Pink Sheet Weekly Trademark Review Nov. 8, 2016
Additional information available to subscribers only: